Levothyroxine Therapy and Cholesterol in Subclinical Hypothyroidism
Author Information
Author(s): Serdar Hiršl Tihana, Đurić Koraljka, Čeprnja Marina, Zec Ivana, Kraljević Šmalcelj Marijana, Jukić Tomislav, Bobetić-Vranić Tanja, Somborac-Bačura Anita
Primary Institution: Synlab Croatia, Polyclinic for Medical Laboratory Diagnostics, Zagreb, Croatia
Hypothesis
Patients with a mild form of subclinical hypothyroidism have significantly higher concentrations of endothelial dysfunction blood markers and that levothyroxine therapy would lower these markers.
Conclusion
Levothyroxine therapy significantly reduces endocan and total cholesterol concentrations in patients with mild subclinical hypothyroidism.
Supporting Evidence
- Patients with subclinical hypothyroidism had higher concentrations of ADMA and endocan compared to healthy controls.
- After 6 months of levothyroxine treatment, endocan and total cholesterol levels significantly decreased.
- Levothyroxine therapy returned TSH levels to normal but still higher than controls.
Takeaway
This study found that giving a medicine called levothyroxine to people with a mild thyroid problem helped lower some bad substances in their blood that can cause heart issues.
Methodology
This was a case-control prospective study where patients with subclinical hypothyroidism and healthy controls were compared before and after 6 months of levothyroxine treatment.
Limitations
The small sample size limits the ability to draw clear conclusions about the benefits of levothyroxine treatment.
Participant Demographics
Participants included 61 adults with mild subclinical hypothyroidism and 30 healthy controls, matched for sex and age.
Statistical Information
P-Value
P = 0.002 for ADMA, P = 0.004 for endocan, P = 0.039 for total cholesterol
Confidence Interval
95% CI of -52.20 to -7.55 for endocan
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website